TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28555207
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant installation in fresh extraction sockets grafted with cortico‐cancellous heterologous bone and porcine derma (group A)
Study: 28555207
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant installation 4 months after tooth extraction and socket preservation using the same materials (group B)
Study: 28555207
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant installation (group A)
Study: 28555207
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant installation (group B)
Study: 10717755
Drug: Chloroquine 25
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 25 mg/kg and 14-days primaquine
Study: 25270857
Drug: Remifentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.5 μg/kg bolus over 60 s followed by 0.05 μg/kg/min continuous infusion for 20 min)
Study: 25270857
Drug: Saline (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9% sodium chloride infusion at a volume and rate equal to that of remifentanil)
Study: 20585896
Drug: Gain-framed message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gain-framed message (describing benefits of receiving the vaccine)
Study: 20585896
Drug: Loss-framed message
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loss-framed message (describing costs of not receiving the vaccine)
Study: 16930145
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with a single dose of amoxicillin and clavulanic acid (group A, n = 193)
Study: 15848701
Drug: Alemtuzumab induction
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab induction (30 mg IV intraoperatively) with rapid corticosteroid elimination
Study: 15848701
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with alternate day rabbit antithymocyte globulin (rATG) induction with a steroid-based regimen
Study: 10354696
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (T)
Study: 8073235
Drug: Insurance supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insurance supplement for unconventional medicine (experimental group)
Study: 8073235
Drug: Self-selected insurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected insurance supplement for unconventional medicine (third group)
Study: 8073235
Drug: No coverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: No coverage of unconventional medicine (control group)
Study: 2645662
Drug: Top-up transfusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top-up transfusions to keep haemoglobin concentrations above 10 g/dl
Study: 2645662
Drug: No transfusions,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No transfusions, allowing haemoglobin concentrations to fall below 10 g/dl
Study: 29768301
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with bevacizumab (457 patients, 128 achieved pCR)
Study: 29768301
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy without bevacizumab
Study: 25482371
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) 1500mg day(-1)
Study: 25482371
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) 1800mg day(-1) + Metformin (MET) 1500mg day(-1)
Study: 9275269
Drug: Prostate specific
Normalized name: Prostate specific antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate specific antigen prescreening followed by digital rectal examination, transrectal ultrasound, and biopsy if indicated.
Study: 1773136
Drug: AHBuBP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHBuBP (5 mg/day on two consecutive days every 3 months for one year)
Study: 1773136
Drug: Calcium (oral)
Normalized name: calcium gluceptate Oral Solution
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (oral)
Study: 30904830
Drug: Methotrexate administration
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate administration
Study: 19685729
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of scalp-acupuncture, body-acupuncture, and abdominal-acupuncture
Study: 31262398
Drug: Trazodone sustained-release
Normalized name: trazodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone sustained-release tablets (TSR)
Study: 31262398
Drug: Trazodone immediate-release
Normalized name: trazodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone immediate-release formulation (TIR)
Study: 31262398
Drug: Multiple dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosage of TSR and TIR
Study: 7797125
Drug: Octreotide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (50 micrograms, subcutaneously, three times daily)
Study: 2152036
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with propofol (group P)
Study: 25814050
Drug: Solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin succinate 5-10 mg daily
Study: 21097688
Drug: Revalor‐X (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revalor‐X (200 mg of TBA and 40 mg of E(2))
Study: 21097688
Drug: Revalor‐IS/S (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revalor‐IS/S (200 mg of TBA and 40 mg of E(2); reimplanted at 68 to 74 d)
Study: 21097688
Drug: Revalor‐S (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revalor‐S (120 mg of TBA and 24 mg of E(2))
Study: 334472
Drug: Flurbiprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (300 mg/day)
Study: 334472
Drug: Aspirin (2.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2.1 g/day)
Study: 334472
Drug: Phenylbutazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (600 mg/day)
Study: 28608601
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment for 8 weeks
Study: 14699368
Drug: Localized high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Localized high-dose UVA1 irradiation
Study: 14699368
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream psoralen-UVA (PUVA)
Study: 9163613
Drug: Aspirin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (40 mg/d)
Study: 3280157
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g bid, orally)
Study: 3280157
Drug: L-carnitine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (3 g as a bolus followed by an infusion of 2 mg/kg/min for 30 min, intravenously)
Study: 23808255
Drug: Glutamine solution
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine solution intravenous use
Study: 3517890
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pyritinol three times daily
Study: 29102514
Drug: omalizumab 150
Normalized name: omalizumab 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omalizumab 150 mg
Study: 25487196
Drug: Wood smoke
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood smoke exposure (1 mg/m³ particulate matter concentration)
Study: 21838788
Drug: Adjusted dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dosing algorithm for HDMTX based on 24 h MTX plasma concentrations.
Study: 21838788
Drug: Standard MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard MTX dose (not explicitly detailed in the abstract).
Study: 21838788
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose (based on dosing algorithm).
Study: 19961836
Drug: Amphetamine (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (an indirect DA agonist)
Study: 19961836
Drug: Haloperidol (DA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (DA D2 receptor antagonist)
Study: 15627855
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT-A) - 25 sessions
Study: 15627855
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT-B) - after contact control period
Study: 15627855
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT-A)
Study: 15627855
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT-B)
Study: 12798827
Drug: Revascularisation in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularisation in addition to optimal medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists, anti-thrombotic agent)
Study: 12798827
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists, anti-thrombotic agent) without revascularisation
Study: 1833121
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg three times a day for 6 weeks)
Study: 1833121
Drug: Acarbose (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (first treatment)
Study: 1833121
Drug: Placebo (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (first treatment)
Study: 1833121
Drug: Acarbose (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (second treatment)
Study: 1833121
Drug: Placebo (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (second treatment)
Study: 6341844
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg with meals and at bedtime)
Study: 6341844
Drug: Antacid (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (15 ml one hour after meals and at bedtime)
Study: 6341844
Drug: Cimetidine and
Normalized name: Cimetidine and sodium alginate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine and Antacid
Study: 29119807
Drug: Beliefs About
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beliefs About Medication Scale (BAMS)
Study: 22077915
Drug: Chemo‐mechanical preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo‐mechanical preparation with no medication
Study: 22077915
Drug: No chemo‐mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemo‐mechanical preparation and no medication
Study: 17255739
Drug: lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir (LPV/r) 533 mg/133 mg twice daily + efavirenz (EFV) 600 mg once daily
Study: 17255739
Drug: EFV +
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EFV + two nucleoside reverse transcriptase inhibitors (NRTI)
Study: 15963081
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg t.d.s. with Omeprazole
Study: 1958158
Drug: Brief intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intensive group cognitive behavioural therapy (2 days)
Study: 31690988
Drug: liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg once daily for 26 weeks
Study: 21333060
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (small-volume nebulizer or 1-hour continuous nebulization)
Study: 19244376
Drug: Bread fortified
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving
Study: 17132479
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including graft augmentation, site-specific repair, and posterior colporrhaphy)
Study: 12767421
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg/ER niacin 2 g
Study: 12767421
Drug: ER niacin
Normalized name: Leader Niacin 500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER niacin 2 g
Study: 12767421
Drug: rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 40 mg/ER niacin 1 g
Study: 10650230
Drug: Diclofenac ophthalmic
Normalized name: diclofenac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac ophthalmic solution
Study: 9579961
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg GBP oral dose in fasting state
Study: 9579961
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg GBP oral dose in fasting state
Study: 9579961
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg GBP oral dose after a high-protein meal
Study: 9579961
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg GBP oral dose after a high-protein meal
Study: 29049890
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly group-based health-related education sessions, 6 months duration, six 1-hour sessions)
Study: 25904498
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% ointment (CP)
Study: 25904498
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 0.1% ointment (MMF)
Study: 22421983
Drug: GLP-1 treatment
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 treatment for 48 hours
Study: 12826783
Drug: Amlodipine/benazepril 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/benazepril 5/10 mg (combination)
Study: 12826783
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg (conventional)
Study: 10982310
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg PGE1 plus 1 mg PHE
Study: 1627943
Drug: Great-dose huanshao
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Great-dose huanshao dan capsules
Study: 1627943
Drug: Great-dose watered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Great-dose watered pills
Study: 1627943
Drug: Small-dose watered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose watered pills
Study: 1627943
Drug: Huanshao dan
Normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huanshao dan and watered pills (combined)
Study: 6370979
Drug: Nomifensine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (100 mg single daily dose)
Study: 29941021
Drug: Fluralaner spot-on
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluralaner spot-on treatment (Bravecto®) at a dose rate of 40 mg/kg, administered topically on Day 0.
Study: 24193155
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg induction infusions at weeks 0, 2, and 6
Study: 18489775
Drug: Probiotic (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Lactobacillus casei rhamnosus) administered at 10^9 colony-forming units twice daily from day 3 to discharge
Study: 1768431
Drug: DOM gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOM gel
Study: 1768431
Drug: Ointments
Normalized name: Cod-liver oil ointments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointments
Study: 1768431
Drug: Creams
Normalized name: ostomy, skin fillers, protective creams & sprays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creams
Study: 1768431
Drug: Gels
Normalized name: Gelsolin
DrugBank: Recombinant human plasma gelsolin (DB15746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gels
Study: 21789590
Drug: G‐Bond (GC
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Bond (GC Corp., Japan) with Gradia resin composite
Study: 11429344
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (initial dose of 10 mg/kg and infusion of 1 mg/kg/h)
Study: 10937295
Drug: Oral decoding
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral decoding of words and pseudowords
Study: 8452273
Drug: Conventional spontaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional spontaneous inhalation induction technique using 4.5% sevoflurane in nitrous oxide and oxygen
Study: 21707252
Drug: Self-administered coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered coping planning intervention
Study: 20629867
Drug: Carbon dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon dioxide (CO(2)) treatment (0% at 96 h, 60% at 48 h, and 60% at 96 h)
Study: 20629867
Drug: Ozone (O(3))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone (O(3)) treatment (0 and 175 ppm for 48 h)
Study: 15844692
Drug: OACA (omeprazole‐amoxicillin‐clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OACA (omeprazole‐amoxicillin‐clarithromycin + aspirin)
Study: 15844692
Drug: OAC (omeprazole‐amoxicillin‐clarithromycin)
Normalized name: AMOXICILLIN/OMEPRAZOLE/RIFABUTIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (omeprazole‐amoxicillin‐clarithromycin)
Study: 12433016
Drug: Nurse-administered educational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered educational and behavioral intervention
Study: 12433016
Drug: Standard-treatment (education)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-treatment (education) control group
Study: 10069685
Drug: Short-acting nifedipine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting nifedipine, 20 mg
Study: 7628131
Drug: simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 10 mg PO QPM
Study: 7628131
Drug: simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 20 mg PO QAM
Study: 7628131
Drug: simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 20 mg PO QPM
Study: 26558544
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (q.d.) lopinavir/ritonavir
Study: 26558544
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily (b.i.d.) lopinavir/ritonavir
Study: 23646932
Drug: ICG-augmented diode
Normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-augmented diode laser treatment (ICG+DL) with λem = 810 nm, 60-110 J cm(‐2), 48-87-ms pulse duration, 6-mm spot size; total ICG dose 4 mg kg(‐1)
Study: 23646932
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser treatment with λem = 1064 nm, 160-240 J cm(‐2), 65-ms pulse duration, 5-mm spot size
Study: 15194018
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of 10/10 mg ezetimibe + simvastatin
Study: 15194018
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of 10/80 mg ezetimibe + simvastatin
Study: 9568167
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of G‐CSF and GM‐CSF at 10 mcg/kg/day (2.5 or 5.0 mcg/kg twice per day)
Study: 9568167
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with G‐CSF or GM‐CSF at 5 mcg/kg/day
Study: 9568167
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with G‐CSF or GM‐CSF at 10 mcg/kg/day
Study: 8041179
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (300 mg dl-alpha-tocopherol 3 times daily for 4 weeks)
Study: 31820131
Drug: Modified-release (MR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release (MR) drug product with a proposed change in dissolution specification; specific dosage and duration not available.
Study: 31820131
Drug: Hypothetical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical formulation with 0% of drug dissolved in 2 hours in in vitro dissolution test; specific dosage and duration not available.
Study: 31820131
Drug: PBPK absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBPK absorption model; specific dosage and duration not available.
Study: 21921700
Drug: Indian tetravalent
Normalized name: Indian frankincense
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indian tetravalent vaccine (Q-Vac (TM))
Study: 21921700
Drug: European tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: European tetravalent vaccine (Tritanrix-HB (TM))
Study: 17039460
Drug: Isomalt (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomalt (30 g per day)
Study: 17039460
Drug: Sucrose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (30 g per day)
Study: 14977341
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia with propofol-remifentanil
Study: 7691912
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal nicotine
Study: 2430512
Drug: 3-day therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day therapy with nalidixic acid
Study: 2430512
Drug: 3-day therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day therapy with trimethoprim/sulphamethoxazole